The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Our interim dividend for 2021 is US$1.04, an increase of 9%
Our exceptionally strong performance is a result of the focused execution of our strategy.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
CSL Appoints New Directors
Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 20…
New National Fractionation Agreement
CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian go…
Expansion of CSL Biotech Facility
CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows wit…
CSL and Vitaeris Strategic Partnership
Agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid or…
CSL112 Phase 3 Clinical Trial
The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 site…
Australian Scientists Awarded $2.5m
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research…
Applications Open for CSL Centenary Fellowship Program
Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million ov…
New Therapy for Diabetic Kidney Disease
An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the prog…
Momenta and CSL Announce Collaboration
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered in…
Popular search terms:
Americas
Asia Pacific
Europe
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
